Privacy-preserving federated analysis reproduces multicentre alteplase compared to tenecteplase (AcT) stroke trial

Cross-jurisdictional clinical trials face increasing barriers from data privacy regulations and governance restrictions that limit centralized individual patient data (IPD) transfer. Federated analysis, where standardized statistical scripts execute locally and only aggregate outputs are shared, offers a privacy-preserving alternative. We evaluated whether a federated analytical framework could reproduce the non-inferiority findings of the Alteplase Compared to Tenecteplase (AcT) randomized controlled trial. We developed Starfish-FL, a general-purpose federated analysis platform, and applied it to AcT IPD from 21 stroke centres across 8 Canadian provinces (n = 1577). The dataset was partitioned by site to emulate a federated environment. Each site computed treatment effect estimates (proportion difference and standard error) for tenecteplase versus alteplase, combined using a fixed-effects federated meta-analytic framework. The primary outcome was excellent functional outcome (modified Rankin Scale [mRS] 0–1 at 90–120 days), with a non-inferiority margin of − 5%. Data from 21 sites comprising 1577 patients (806 tenecteplase, 771 alteplase) were included. Reproducing AcT's crude estimation from the same site partition yielded a risk difference of 2.14% (95% CI − 2.61 to 6.88%) for the primary outcome against 2.1% (95% CI − 2.6 to 6.9%) in the original centralized analysis, matching on the estimate and both interval bounds. The site-stratified federated estimator yielded 2.12% (95% CI − 2.53 to 6.77%). Non-inferiority was met under both. All four outcomes reproduced the published result at the published precision, so mRS 0–2 at 0.80% against 0.8%, symptomatic intracerebral haemorrhage at 0.23% against 0.2%, and 90-day mortality at − 0.11% against − 0.1%. Non-inferiority held under all ten sensitivity specifications examined, with the lower confidence bound between − 2.95 and − 2.09% throughout. A federated analytical framework reproduced the non-inferiority conclusions of a large multicentre randomized stroke trial without cross-border IPD transfer. Validated federated infrastructures offer a scalable, privacy-preserving paradigm for future global clinical research.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-15
DOI
https://doi.org/10.1038/s41598-026-79654-0
Primary Topic
Privacy-Preserving Technologies in Data
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Privacy-preserving federated analysis reproduces multicentre alteplase compared to tenecteplase (AcT) stroke trial

Kauê Tartarotti Nepomuceno Duarte, Jessalyn K. Holodinsky, Bijoy K. Menon, Tolulope T. Sajobi et al.
3 links
Scientific Reports
Privacy-Preserving Technologies in Data
article

Privacy-preserving federated analysis reproduces multicentre alteplase compared to tenecteplase (AcT) stroke trial

Kauê Tartarotti Nepomuceno Duarte, Jessalyn K. Holodinsky, Bijoy K. Menon, Tolulope T. Sajobi, Steve Drew, Z.S. Saad, Farhan Abbas, Yunkai Bao
article en

Abstract

Cross-jurisdictional clinical trials face increasing barriers from data privacy regulations and governance restrictions that limit centralized individual patient data (IPD) transfer. Federated analysis, where standardized statistical scripts execute locally and only aggregate outputs are shared, offers a privacy-preserving alternative. We evaluated whether a federated analytical framework could reproduce the non-inferiority findings of the Alteplase Compared to Tenecteplase (AcT) randomized controlled trial. We developed Starfish-FL, a general-purpose federated analysis platform, and applied it to AcT IPD from 21 stroke centres across 8 Canadian provinces (n = 1577). The dataset was partitioned by site to emulate a federated environment. Each site computed treatment effect estimates (proportion difference and standard error) for tenecteplase versus alteplase, combined using a fixed-effects federated meta-analytic framework. The primary outcome was excellent functional outcome (modified Rankin Scale [mRS] 0–1 at 90–120 days), with a non-inferiority margin of − 5%. Data from 21 sites comprising 1577 patients (806 tenecteplase, 771 alteplase) were included. Reproducing AcT's crude estimation from the same site partition yielded a risk difference of 2.14% (95% CI − 2.61 to 6.88%) for the primary outcome against 2.1% (95% CI − 2.6 to 6.9%) in the original centralized analysis, matching on the estimate and both interval bounds. The site-stratified federated estimator yielded 2.12% (95% CI − 2.53 to 6.77%). Non-inferiority was met under both. All four outcomes reproduced the published result at the published precision, so mRS 0–2 at 0.80% against 0.8%, symptomatic intracerebral haemorrhage at 0.23% against 0.2%, and 90-day mortality at − 0.11% against − 0.1%. Non-inferiority held under all ten sensitivity specifications examined, with the lower confidence bound between − 2.95 and − 2.09% throughout. A federated analytical framework reproduced the non-inferiority conclusions of a large multicentre randomized stroke trial without cross-border IPD transfer. Validated federated infrastructures offer a scalable, privacy-preserving paradigm for future global clinical research.

Scientific Reports
University of Calgary (CA), O'Brien Institute (AU), Hotchkiss Brain Institute (CA)
Good health and well-being
Privacy-Preserving Technologies in Data
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon